Abstract
Artificial intelligence (AI) has huge potential to improve the health and well-being of people, but adoption in clinical practice is still limited. Lack of transparency is identified as one of the main barriers to implementation, as clinicians should be confident the AI system can be trusted. Explainable AI has the potential to overcome this issue and can be a step towards trustworthy AI. In this paper we review the recent literature to provide guidance to researchers and practitioners on the design of explainable AI systems for the health-care domain and contribute to formalization of the field of explainable AI. We argue the reason to demand explainability determines what should be explained as this determines the relative importance of the properties of explainability (i.e. interpretability and fidelity). Based on this, we propose a framework to guide the choice between classes of explainable AI methods (explainable modelling versus post-hoc explanation; model-based, attribution-based, or example-based explanations; global and local explanations). Furthermore, we find that quantitative evaluation metrics, which are important for objective standardized evaluation, are still lacking for some properties (e.g. clarity) and types of explanations (e.g. example-based methods). We conclude that explainable modelling can contribute to trustworthy AI, but the benefits of explainability still need to be proven in practice and complementary measures might be needed to create trustworthy AI in health care (e.g. reporting data quality, performing extensive (external) validation, and regulation).
Original language | English |
---|---|
Article number | 103655 |
Journal | Journal of Biomedical Informatics |
Volume | 113 |
DOIs | |
Publication status | Published - Jan 2021 |
Bibliographical note
Funding Information:The authors like to thank Dr. Jenna Reps for her valuable feedback on this manuscript. This project has received support from the European Health Data and Evidence Network (EHDEN) project. EHDEN received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.
Funding Information:
This project has received support from the European Health Data and Evidence Network (EHDEN) project. EHDEN received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Publisher Copyright:
© 2020 The Authors